Hillsdale Investment Management Inc.
Position in RLMD — Relmada Therapeutics, Inc.
CIK 1368465
Toronto, A6
Position in RLMD
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$373,056
New position
Shares Held
53,600
first reported quarter
Ownership
0.051%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 2.6119402985074625.ToString("F0")%
Shared 0.ToString("F0")%
None 97.38805970149254.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Hillsdale Investment Management Inc. holds $85,671,146 across 25 Biotechnology names. RLMD ranks #18 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
167,742 | $12,456,520 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
53,363 | $9,019,414 | |
| 3 | ZYME |
Zymeworks Inc.
|
345,622 | $8,654,374 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
110,050 | $7,112,531 | |
| 5 | MIRM |
Mirum Pharmaceuticals, Inc.
|
59,730 | $5,517,857 | |
| 6 | ENTA |
Enanta Pharmaceuticals Inc
|
435,510 | $5,500,491 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
182,320 | $5,416,727 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
70,900 | $5,323,881 |
All Filings in RLMD
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $373,056 | 53,600 | Shares | Sole | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||